These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
48. [Letter: Significance of Toxoplasma infections for public health]. Koppe JG Ned Tijdschr Geneeskd; 1975 Sep; 119(38):1477. PubMed ID: 1165816 [No Abstract] [Full Text] [Related]
49. Long-term outcome of children with congenital toxoplasmosis. Berrébi A; Assouline C; Bessières MH; Lathière M; Cassaing S; Minville V; Ayoubi JM Am J Obstet Gynecol; 2010 Dec; 203(6):552.e1-6. PubMed ID: 20633868 [TBL] [Abstract][Full Text] [Related]
50. Simultaneous determination of pyrimethamine, sulfadiazine and N-acetyl-sulfadiazine in plasma for monitoring infants in treatment of congenital toxoplasmosis. Johannessen JK; Christiansen I; Schmidt DR; Petersen E; Hansen SH J Pharm Biomed Anal; 2005 Jan; 36(5):1093-8. PubMed ID: 15620537 [TBL] [Abstract][Full Text] [Related]
51. [In utero treatment of congenital toxoplasmosis with a pyrimethamine-sulfadiazine combination]. Couvreur J Presse Med; 1991 Jun; 20(24):1136. PubMed ID: 1830148 [No Abstract] [Full Text] [Related]
52. Congenital toxoplasmosis: prenatal diagnosis, treatment and postnatal outcome. Friedman S; Ford-Jones LE; Toi A; Ryan G; Blaser S; Chitayat D Prenat Diagn; 1999 Apr; 19(4):330-3. PubMed ID: 10327137 [TBL] [Abstract][Full Text] [Related]
53. Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis. Soheilian M; Sadoughi MM; Ghajarnia M; Dehghan MH; Yazdani S; Behboudi H; Anisian A; Peyman GA Ophthalmology; 2005 Nov; 112(11):1876-82. PubMed ID: 16171866 [TBL] [Abstract][Full Text] [Related]
55. [Possibilities of preventing and combating congenital toxoplasmosis]. Arseni C; Ciurea V; Horvath L Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1979; 24(4):251-7. PubMed ID: 531389 [No Abstract] [Full Text] [Related]
56. Association between IgG subclasses against Toxoplasma gondii and clinical signs in newborns with congenital toxoplasmosis. de Souza-e-Silva CH; Vasconcelos-Santos DV; de Andrade GQ; Carellos EV; de Castro Romanelli RM; de Resende LM; Januário JN; Carneiro M; de Aguiar Vasconcelos Carneiro AC; de Almeida Vitor RW Pediatr Infect Dis J; 2013 Jan; 32(1):13-6. PubMed ID: 22935868 [TBL] [Abstract][Full Text] [Related]
57. [Management of congenital toxoplasmosis in France: current data]. Garcia-Méric P; Franck J; Dumon H; Piarroux R Presse Med; 2010 May; 39(5):530-8. PubMed ID: 19926248 [TBL] [Abstract][Full Text] [Related]
58. Cataracts in congenital toxoplasmosis. Arun V; Noble AG; Latkany P; Troia RN; Jalbrzikowski J; Kasza K; Karrison T; Cezar S; Sautter M; Greenwald MJ; Mieler W; Mets MB; Alam A; Boyer K; Swisher CN; Roizen N; Rabiah P; Del Monte MA; McLeod R; J AAPOS; 2007 Dec; 11(6):551-4. PubMed ID: 18086432 [TBL] [Abstract][Full Text] [Related]
60. Randomized controlled trial of pyrimethamine plus sulfadiazine versus trimethoprim plus sulfamethoxazole for treatment of toxoplasmic encephalitis in AIDS patients. Kongsaengdao S; Samintarapanya K; Oranratnachai K; Prapakarn W; Apichartpiyakul C J Int Assoc Physicians AIDS Care (Chic); 2008; 7(1):11-6. PubMed ID: 17517949 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]